Intensive LDL-cholesterol lowering therapy and neurocognitive function

Pharmacology and Therapeutics

Volumn 170, Issue , 2017, Pages 181-191

  Banach, Maciej ^a,b   Rizzo, Manfredi ^c,d   Nikolic, Dragana ^c   Howard, George ^e   Howard, Virginia J ^e   Mikhailidis, Dimitri P ^f  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^c UNIVERSITY OF PALERMO   (Italy)

^d Euro Mediterranean Institute of Science and Technology   (Italy)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Lipid lowering drugs; Low density lipoprotein cholesterol; Neurocognitive function; Proprotein convertase subtilisin kexin type 9; Statins

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERINE PROTEINASE INHIBITOR; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

AMNESIA; CHOLESTEROL INTAKE; COGNITION; COGNITIVE DEFECT; DEMENTIA; HUMAN; HYPERLIPIDEMIA; META ANALYSIS (TOPIC); PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; AGE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; FEMALE; MALE; NEUROCOGNITIVE DISORDERS; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; ANIMALS; CHOLESTEROL, LDL; COGNITION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MALE; NEUROCOGNITIVE DISORDERS; PROPROTEIN CONVERTASE 9; RISK FACTORS; SEX FACTORS;

EID: 85006905988     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.11.001     Document Type: Review

References (98)

1. Alfred, T., Ben-Shlomo, Y., Cooper, R., Hardy, R., Cooper, C., Deary, I.J., et al., HALCyon Study Team, Associations between APOE and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: The HALCyon programme. Age (Dordrecht, Netherlands), 36, 2014, 9673.
2. Alkindi, M., Siminovitch, K.A., Gupta, M., Genest, J., Monoclonal antibodies for the treatment of hypercholesterolemia: Targeting PCSK9. The Canadian Journal of Cardiology, 2016 (pii: S0828-0282X(0816)30057-30055).
3. Amgen, Amgen announces positive top-line results from phase 3 GAUSS-3 trial of Repatha (evolocumab) in statin-intolerant patients with high cholesterol [press release]. 2016, February 4.
4. Ancelin, M.L., Ripoche, E., Dupuy, A.M., Samieri, C., Rouaud, O., Berr, C., et al. Gender-specific associations between lipids and cognitive decline in the elderly. European Neuropsychopharmacology 24 (2014), 1056–1066.
5. Arvanitakis, Z., Schneider, J.A., Wilson, R.S., Bienias, J.L., Kelly, J.F., Evans, D.A., et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70 (2008), 1795–1802.
6. Aydin, U., Ugurlucan, M., Gungor, F., Ziyade, S., Inan, B., Banach, M., et al. Effects of atorvastatin on vascular intimal hyperplasia: An experimental rodent model. Angiology 60 (2009), 370–377.
7. Banach, M., Serban, M.C., Discussion around statin discontinuation in older adults and patients with wasting diseases. Journal of Cachexia, Sarcopenia and Muscle 7 (2016), 396–399.
8. Banach, M., Aronow, W.S., Serban, M.C., Rysz, J., Voroneanu, L., Covic, A., Lipids, blood pressure and kidney update 2015. Lipids in Health and Disease, 14, 2015, 167.
9. Banach, M., Rizzo, M., Obradovic, M., Montalto, G., Rysz, J., Mikhailidis, D.P., et al. PCSK9 inhibition - A novel mechanism to treat lipid disorders?. Current Pharmaceutical Design 19 (2013), 3869–3877.
10. Banach, M., Rizzo, M., Toth, P.P., Farnier, M., Davidson, M.H., Al-Rasadi, K., et al. Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opinion on Drug Safety 14 (2015), 935–955.
11. Banach, M., Rizzo, M., Toth, P.P., Farnier, M., Davidson, M.H., Al-Rasadi, K., et al. Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science 11 (2015), 1–23.
12. Banach, M., Stulc, T., Dent, R., Toth, P.P., Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology 225 (2016), 184–196.
13. Barone, E., Di Domenico, F., Butterfield, D.A., Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets. Biochemical Pharmacology 88 (2014), 605–616.
14. Belinson, H., Lev, D., Masliah, E., Michaelson, D.M., Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. The Journal of Neuroscience 28 (2008), 4690–4701.
15. Benito-Leon, J., Vega-Quiroga, S., Villarejo-Galende, A., Bermejo-Pareja, F., Hypercholesterolemia in elders is associated with slower cognitive decline: A prospective, population-based study (NEDICES). Journal of the Neurological Sciences 350 (2015), 69–74.
16. Burns, M., Duff, K., Cholesterol in Alzheimer's disease and tauopathy. Annals of the New York Academy of Sciences 977 (2002), 367–375.
17. Butterfield, D.A., Barone, E., Mancuso, C., Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacological Research 64 (2011), 180–186.
18. Camerino, G.M., De Bellis, M., Conte, E., Liantonio, A., Musaraj, K., Cannone, M., et al. Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. Toxicology and Applied Pharmacology 306 (2016), 36–46.
19. ClinicalTrials.gov NCT01764633, Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). https://clinicaltrials.gov/ct2/show/NCT01764633.
20. ClinicalTrials.gov NCT02207634, Evaluating PCSK9 binding antiBody influence oN coGnitive HeAlth in high cardiovascUlar risk subjects (EBBINGHAUS). https://clinicaltrials.gov/ct2/show/NCT02207634.
21. Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr., Hobbs, H.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. The New England Journal of Medicine 354 (2006), 1264–1272.
22. Cucchiara, B., Kasner, S.E., Use of statins in CNS disorders. Journal of the Neurological Sciences 187 (2001), 81–89.
23. Cuciureanu, M., Vlase, L., Muntean, D., Varlan, I., Cuciureanu, R., Grapefruit juice–drug interactions: Importance for pharmacotherapy. Revista Medico-Chirurgicala A Societatii de Medici si Naturalisti din Iasi 114 (2010), 885–891.
24. Dietschy, J.M., Turley, S.D., Cholesterol metabolism in the brain. Current Opinion in Lipidology 12 (2001), 105–112.
25. Dragan, S., Serban, M.C., Banach, M., Proprotein convertase subtilisin/kexin 9 inhibitors: An emerging lipid-lowering therapy?. Journal of Cardiovascular Pharmacology and Therapeutics 20 (2015), 157–168.
26. Eckert, G.P., Hooff, G.P., Strandjord, D.M., Igbavboa, U., Volmer, D.A., Muller, W.E., et al. Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiology of Disease 35 (2009), 251–257.
27. Evans, M.A., Golomb, B.A., Statin-associated adverse cognitive effects: Survey results from 171 patients. Pharmacotherapy 29 (2009), 800–811.
28. Everett, B.M., Smith, R.J., Hiatt, W.R., Reducing LDL with PCSK9 inhibitors—The clinical benefit of lipid drugs. The New England Journal of Medicine 373 (2015), 1588–1591.
29. Feldman, H.H., Doody, R.S., Kivipelto, M., Sparks, D.L., Waters, D.D., Jones, R.W., et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74 (2010), 956–964.
30. Galasko, D.R., Peskind, E., Clark, C.M., Quinn, J.F., Ringman, J.M., Jicha, G.A., et al., Alzheimer's Disease Cooperative Study, Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology 69 (2012), 836–841.
31. Ghosh, A., Roy, A., Matras, J., Brahmachari, S., Gendelman, H.E., Pahan, K., Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. The Journal of Neuroscience 29 (2009), 13543–13556.
32. Goh, I.X., How, C.H., Tavintharan, S., Cytochrome P450 drug interactions with statin therapy. Singapore Medical Journal 54 (2013), 131–135.
33. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
34. Helzner, E.P., Luchsinger, J.A., Scarmeas, N., Cosentino, S., Brickman, A.M., Glymour, M.M., et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Archives of Neurology 66 (2009), 343–348.
35. Henderson, V.W., Guthrie, J.R., Dennerstein, L., Serum lipids and memory in a population based cohort of middle age women. Journal of Neurology, Neurosurgery, and Psychiatry 74 (2003), 1530–1535.
36. Hobbs, F.D., Banach, M., Mikhailidis, D.P., Malhotra, A., Capewell, S., Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Medicine, 14, 2016, 4.
37. Hyttinen, L., TuulioHenriksson, A., Vuorio, A.F., Kuosmanen, N., Harkanen, T., Koskinen, S., et al. Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls. Journal of Alzheimer's Disease 21 (2010), 611–617.
38. Ikonen, E., Cellular cholesterol trafficking and compartmentalization. Nature Reviews. Molecular Cell Biology 9 (2008), 125–138.
39. Ito, M.K., Santos, R.D., PCSK9 inhibition with monoclonal antibodies—Modern management of hypercholesterolemia. Journal of Clinical Pharmacology, 2016 (Epub ahead of print).
40. Jones, R.W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D.D., et al. The atorvastatin/donepezil in Alzheimer's disease study (LEADe): Design and baseline characteristics. Alzheimers Dement 4 (2008), 145–153.
41. Katsumata, Y., Todoriki, H., Higashiuesato, Y., Yasura, S., Ohya, Y., Willcox, D.C., et al. Very old adults with better memory function have higher low-density lipoprotein cholesterol levels and lower triglyceride to high-density lipoprotein cholesterol ratios: KOCOA project. Journal of Alzheimer's Disease 34 (2013), 273–279.
42. Kereiakes, D.J., Robinson, J.G., Cannon, C.P., Lorenzato, C., Pordy, R., Chaudhari, U., et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. American Heart Journal, 169(906-915), 2015, e913.
43. Korinek, M., Vyklicky, V., Borovska, J., Lichnerova, K., Kaniakova, M., Krausova, B., et al. Cholesterol modulates open probability and desensitization of NMDA receptors. The Journal of Physiology 593 (2015), 2279–2293.
44. Kotowski, I.K., Pertsemlidis, A., Luke, A., Cooper, R.S., Vega, G.L., Cohen, J.C., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. American Journal of Human Genetics 78 (2006), 410–422.
45. Krakowski, M., Czobor, P., Cholesterol and cognition in schizophrenia: A double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophrenia Research 130 (2011), 27–33.
46. Leritz, E.C., McGlinchey, R.E., Salat, D.H., Milberg, W.P., Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory. Metabolic Brain Disease 31 (2016), 465–473.
47. Ling, Q., Tejada-Simon, M.V., Statins and the brain: New perspective for old drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 66 (2016), 80–86.
48. Lipinski, M.J., Benedetto, U., Escarcega, R.O., Biondi-Zoccai, G., Lhermusier, T., Baker, N.C., et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis. European Heart Journal 37 (2016), 536–545.
49. Ma, L., Feng, M., Qian, Y., Yang, W., Liu, J., Han, R., et al. Insulin resistance is an important risk factor for cognitive impairment in elderly patients with primary hypertension. Yonsei Medical Journal 56 (2015), 89–94.
50. McGuinness, B., Craig, D., Bullock, R., Passmore, P., Statins for the prevention of dementia. Cochrane Database of Systematic Reviews, 2016, CD003160.
51. Michikawa, M., Cholesterol paradox: Is high total or low HDL cholesterol level a risk for Alzheimer's disease?. Journal of Neuroscience Research 72 (2003), 141–146.
52. Mospan, C.M., Are statins protective or harmful to cognitive function?. JAAPA 29 (2016), 11–12.
53. Muntean, D.M., Thompson, P.D., Catapano, A.L., Stasiolek, M., Fabis, J., Muntner, P., et al. Statin-associated myopathy and the quest for biomarkers: Can we effectively predict statin-associated muscle symptoms?. Drug Discovery Today, 2016, 10.1016/j.drudis.2016.09.001.
54. Ngandu, T., Lehtisalo, J., Solomon, A., Levalahti, E., Ahtiluoto, S., Antikainen, R., et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet 385 (2015), 2255–2263.
55. O'Neil, A., Sanna, L., Redlich, C., Sanderson, K., Jacka, F., Williams, L.J., et al. The impact of statins on psychological wellbeing: A systematic review and meta-analysis. BMC Medicine, 10, 2012, 154.
56. Osterweil, E.K., Chuang, S.C., Chubykin, A.A., Sidorov, M., Bianchi, R., Wong, R.K., et al. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77 (2013), 243–250.
57. Ott, B.R., Daiello, L.A., Dahabreh, I.J., Springate, B.A., Bixby, K., Murali, M., et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. Journal of General Internal Medicine 30 (2015), 348–358.
58. Parsaik, A.K., Singh, B., Murad, M.H., Singh, K., Mascarenhas, S.S., Williams, M.D., et al. Statins use and risk of depression: A systematic review and meta-analysis. Journal of Affective Disorders 160 (2014), 62–67.
59. Peng, W., Qiang, F., Peng, W., Qian, Z., Ke, Z., Yi, L., et al. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. International Journal of Cardiology 222 (2016), 119–129.
60. Proitsi, P., Lupton, M.K., Velayudhan, L., Newhouse, S., Fogh, I., Tsolaki, M., et al. Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: A Mendelian randomization analysis. PLoS Medicine, 11, 2014, e1001713.
61. Raygani, A.V., Rahimi, Z., Kharazi, H., Tavilani, H., Pourmotabbed, T., Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neuroscience Letters 408 (2006), 68–72.
62. Rea, T.D., Breitner, J.C., Psaty, B.M., Fitzpatrick, A.L., Lopez, O.L., Newman, A.B., et al. Statin use and the risk of incident dementia: The cardiovascular health study. Archives of Neurology 62 (2005), 1047–1051.
63. Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H.C., Jagust, W., Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurology 71 (2014), 195–200.
64. Reiner, Z., Catapano, A.L., De Backer, G., Graham, I., Taskinen, M.R., Wiklund, O., et al., Clinical Practice Guidelines Committee of the Spanish Society of Cardiology, ESC/EAS guidelines for the management of dyslipidaemias. Revista Española de Cardiología, 64, 2011 (1168 e1161-1168 e1160).
65. Reitz, C., Tang, M.X., Luchsinger, J., Mayeux, R., Relation of plasma lipids to Alzheimer disease and vascular dementia. Archives of Neurology 61 (2004), 705–714.
66. Richardson, K., Schoen, M., French, B., Umscheid, C.A., Mitchell, M.D., Arnold, S.E., et al. Statins and cognitive function: A systematic review. Annals of Internal Medicine 159 (2013), 688–697.
67. Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., et al., Odyssey Long Term Investigators, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. The New England Journal of Medicine 372 (2015), 1489–1499.
68. Rockwood, K., Kirkland, S., Hogan, D.B., MacKnight, C., Merry, H., Verreault, R., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Archives of Neurology 59 (2002), 223–227.
69. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Ballantyne, C.M., Somaratne, R., et al. Effect of the PCSK9 inhibitor evolocumab on cardiovascular outcomes. American College of Cardiology 2015 scientific sessions; march 15, 2015; San Diego, CA. Abstract 402-08, 2015 ( http://www.abstractsonline.com/pp8/#!/3658/presentation/37603).
70. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., et al., Open-Label Study of Long-Term Evaluation against LDL Cholesterol Investigators, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. The New England Journal of Medicine 372 (2015), 1500–1509.
71. Sahebkar, A., Kotani, K., Serban, C., Ursoniu, S., Mikhailidis, D.P., Jones, S.R., et al., Lipid and Blood Pressure Meta-analysis Collaboration Group. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis 241 (2015), 433–442.
72. Sato, N., Morishita, R., The roles of lipid and glucose metabolism in modulation of beta-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Frontiers in Aging Neuroscience, 7, 2015, 199.
73. Schonknecht, P., Lutjohann, D., Pantel, J., Bardenheuer, H., Hartmann, T., von Bergmann, K., et al. Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neuroscience Letters 324 (2002), 83–85.
74. Serajuddin, A.T., Ranadive, S.A., Mahoney, E.M., Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. Journal of Pharmaceutical Sciences 80 (1991), 830–834.
75. Serban, M.C., Banach, M., Mikhailidis, D.P., Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opinion on Pharmacotherapy 17 (2016), 369–380.
76. Serban, C., Sahebkar, A., Ursoniu, S., Mikhailidis, D.P., Rizzo, M., Lip, G.Y., et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Scientific Reports, 5, 2015, 9902.
77. Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M., et al., Prosper study group. PROspective Study of Pravastatin in the Elderly at Risk, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360 (2002), 1623–1630.
78. Simpson, R.J. Jr., Mendys, P., The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review. Journal of Clinical Lipidology 4 (2010), 462–471.
79. Sims, R., Madhere, S., Callender, C., Campbell, A. Jr., Patterns of relationships between cardiovascular disease risk factors and neurocognitive function in African Americans. Ethnicity & Disease 18 (2008), 471–476.
80. Singh-Manoux, A., Czernichow, S., Elbaz, A., Dugravot, A., Sabia, S., Hagger-Johnson, G., et al. Obesity phenotypes in midlife and cognition in early old age: The Whitehall II cohort study. Neurology 79 (2012), 755–762.
81. Solfrizzi, V., D'Introno, A., Colacicco, A.M., Capurso, C., Todarello, O., Pellicani, V., et al. Circulating biomarkers of cognitive decline and dementia. Clinica Chimica Acta 364 (2006), 91–112.
82. Sparks, D.L., Connor, D.J., Browne, P.J., Lopez, J.E., Sabbagh, M.N., HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. The Journal of Nutrition, Health & Aging 6 (2002), 324–331.
83. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 63 (2014), 2889–2934.
84. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (2014), S1–45.
85. Strom, B.L., Schinnar, R., Karlawish, J., Hennessy, S., Teal, V., Bilker, W.B., Statin therapy and risk of acute memory impairment. JAMA Internal Medicine 175 (2015), 1399–1405.
86. Swiger, K.J., Martin, S.S., PCSK9 inhibitors and neurocognitive adverse events: Exploring the FDA directive and a proposal for N-of-1 trials. Drug Safety 38 (2015), 519–526.
87. Swiger, K.J., Manalac, R.J., Blumenthal, R.S., Blaha, M.J., Martin, S.S., Statins and cognition: A systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clinic Proceedings 88 (2013), 1213–1221.
88. Szwast, S.J., Hendrie, H.C., Lane, K.A., Gao, S., Taylor, S.E., Unverzagt, F., et al. Association of statin use with cognitive decline in elderly African Americans. Neurology 69 (2007), 1873–1880.
89. US Food and Drug Administration, FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm, 2012, February 28.
90. van Vliet, P., Westendorp, R.G., van Heemst, D., de Craen, A.J., Oleksik, A.M., Cognitive decline precedes late-life longitudinal changes in vascular risk factors. Journal of Neurology, Neurosurgery, and Psychiatry 81 (2010), 1028–1032.
91. Wagstaff, L.R., Mitton, M.W., Arvik, B.M., Doraiswamy, P.M., Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy 23 (2003), 871–880.
92. Williamson, J.D., Launer, L.J., Bryan, R.N., Coker, L.H., Lazar, R.M., Gerstein, H.C., et al., Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes, Investigators, Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: A randomized clinical trial. JAMA Internal Medicine 174 (2014), 324–333.
93. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G.G., Siegel, G., Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 57 (2000), 1439–1443.
94. Wood, W.G., Mupsilonller, W.E., Eckert, G.P., Statins and neuroprotection: Basic pharmacology needed. Molecular Neurobiology 50 (2014), 214–220.
95. Yamagishi, K., Ikeda, A., Moriyama, Y., Chei, C.L., Noda, H., Umesawa, M., et al., Circs Investigators, Serum coenzyme Q10 and risk of disabling dementia: The Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 237 (2014), 400–403.
96. Yang, T., Sun, Y., Lu, Z., Leak, R.K., Zhang, F., The impact of cerebrovascular aging on vascular cognitive impairment and dementia. Ageing Research Reviews, 2016 (pii: S1568-1637(1516)30118-30110).
97. Zanchetti, A., Liu, L., Mancia, G., Parati, G., Grassi, G., Stramba-Badiale, M., et al. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: A review of available trial evidence. Journal of Hypertension 32 (2014), 1741–1750.
98. Zou, Y., Zhu, Q., Deng, Y., Duan, J., Pan, L., Tu, Q., et al. Vascular risk factors and mild cognitive impairment in the elderly population in Southwest China. American Journal of Alzheimer's Disease and Other Dementias 29 (2014), 242–247.